Federal judge tosses out antitrust lawsuit against Eli Lilly, Sanofi over diabetes drug discounts
A federal judge in New York dismissed an antitrust lawsuit against drugmakers alleging that they conspired to boost profits by limiting discounts on insulin beginning in 2020.
Mosaic Health and Central Virginia Health Services, both nonprofit healthcare providers, filed the lawsuit in 2021 in the US District Court for the Western District of New York. They alleged that Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca broke state and federal laws by “suddenly, and in coordination with one another,” agreeing to limit drug discounts through the federal 340B program, which allows safety-net hospitals and clinics to buy drugs like insulin at cheaper prices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.